The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor.
about
Salinomycin as a drug for targeting human cancer stem cellsSide population cells as prototype of chemoresistant, tumor-initiating cellsSalinomycin: a novel anti-cancer agent with known anti-coccidial activitiesThe EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.Salinomycin induces autophagy in colon and breast cancer cells with concomitant generation of reactive oxygen speciesSalinomycin activates AMP-activated protein kinase-dependent autophagy in cultured osteoblastoma cells: a negative regulator against cell apoptosisSalinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell linesABC transporters in CSCs membranes as a novel target for treating tumor relapse.Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance.iTEP nanoparticle-delivered salinomycin displays an enhanced toxicity to cancer stem cells in orthotopic breast tumors.Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 proteinMultiple drug resistance due to resistance to stem cells and stem cell treatment progress in cancer (Review).Synthetic modification of salinomycin: selective O-acylation and biological evaluation.Differential effects of drugs targeting cancer stem cell (CSC) and non-CSC populations on lung primary tumors and metastasisThe role of breast cancer stem cells in metastasis and therapeutic implications.Salinomycin inhibits the tumor growth of glioma stem cells by selectively suppressing glioma-initiating cells.Getting to the source: selective drug targeting of cancer stem cells.Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells.Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR human breast cancer cells via decreased efflux of doxorubicin.ROS-p53-cyclophilin-D signaling mediates salinomycin-induced glioma cell necrosisCurcumin: updated molecular mechanisms and intervention targets in human lung cancer.Breast cancer stem cell selectivity of synthetic nanomolar-active salinomycin analogsDrug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics.Structure-Activity Relationships in Salinomycin: Cytotoxicity and Phenotype Selectivity of Semi-synthetic Derivatives.Lower salinomycin concentration increases apoptotic detachment in high-density cancer cells.The implications of cancer stem cells for cancer therapy.Inhibition of the autophagic flux by salinomycin in breast cancer stem-like/progenitor cells interferes with their maintenanceSalinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2.Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells.Cancer stem cells in breast cancer.Tetrandrine, a Compound Common in Chinese Traditional Medicine, Preferentially Kills Breast Cancer Tumor Initiating Cells (TICs) In VitroCombination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy.Low amount of salinomycin greatly increases Akt activation, but reduces activated p70S6K levelsCancer stem cell drugs target K-ras signaling in a stemness context.Colon cancer stem cells: implications in carcinogenesis.Breast cancer stem cells: treatment resistance and therapeutic opportunities.Cancer stem cells and cancer therapy.Cancer stem cells: the development of new cancer therapeutics.Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells.Nigericin decreases the viability of multidrug-resistant cancer cells and lung tumorspheres and potentiates the effects of cardiac glycosides.
P2860
Q21285139-0BB00C61-891D-4D71-8E80-CFCE6EBFF1A4Q26823433-295B7741-1164-4AC9-A399-ABBF53CF2076Q26853644-C1A2925E-7D36-40CA-899D-1DF5D2D36F00Q27852536-0795FE2C-577D-40EC-A689-A5DD5B690126Q28483896-0DE34C20-B0DD-4B84-B3E1-AE718C5D2A75Q28537665-7F94D76E-7F25-47AC-BD56-C0079ABFD82DQ28537942-C6F5AB72-F5F0-4C32-B8F4-146EAEDBB8E7Q33879326-9BA9E7CF-D6CF-482B-B9BA-C75CB80D1D12Q34208986-6FBF2902-DE41-4318-A456-1E9E00D47FAAQ34435742-740E9EEE-06B3-44FD-A080-37F7E1DE0C24Q34583585-DD09DF1C-A212-49C0-A1BA-A65602552B46Q34795591-AB3C8E06-9F6A-4D6B-9985-151E0FD6DC76Q34987533-AC7A7EF8-DE00-46D7-831C-0E518F447BA1Q35053270-6FD085DD-6A35-4416-8D94-918871D94FF6Q35070157-54E18805-BCC5-455C-AFC9-C14E9117E261Q35111314-EDC53FEA-1511-4EA5-AC00-BB18F16B6C92Q35156404-FAA9774A-6996-42D3-B87B-C2C9107E76E8Q35164584-9F5FF94B-173B-4CCC-8A94-D765F5537E45Q35609552-A382890E-6D02-4765-8455-361A124F1614Q35801577-5799B495-B90F-4D88-9E8B-E8DFAAFB5F89Q35866113-D8EAE2E5-6405-4E6A-B276-318AF6BD580AQ35932396-A6D9C90B-1C8A-44B1-B2A2-4BEAC116B429Q35975423-5EE7DC03-5463-49F1-998C-FD8DE49F9437Q36163555-A1AE75FC-E963-49FB-BB3F-0A1515DC3E69Q36396532-4D34ED98-C9A0-4973-993F-EF66171815E3Q36538487-DBEB2BED-A443-4682-AA1A-258FBC9B0B67Q36892078-FE77C922-6AED-4383-864A-E869AE56F1DFQ36985137-BE46AF50-0A7B-4E98-B88D-D13C23229DF1Q37043022-469F858F-74A7-4B11-9183-6C5D2D460D9DQ37129887-59559B34-CA8D-4E7F-9623-4C87547480E3Q37132754-92C024A4-C23E-4225-B994-69A61A37FC15Q37158877-31F17B2D-4D84-45A4-BB21-966185F6AFF9Q37225029-FA9E07B6-4272-4890-BEA8-7E702572DA36Q37325194-015CC3C6-962C-492C-96FC-AAB443E9BB7AQ37825224-16F09F5A-C3D5-4A81-ACAC-F13945AE36DCQ37839530-FA7CA602-48AF-4831-B2EC-A5E07F57E1DDQ37841186-B399C17D-65A2-48FC-9B02-53E617092DE6Q37861207-F55962B1-F7A6-4D32-98F3-3DBE7C4CE011Q38322466-61AF3BA1-CF2A-4A91-9654-06E94A1D2C36Q38709867-4FECF8E4-148B-4A6E-943F-831384BCDCBA
P2860
The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor.
@en
The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor.
@nl
type
label
The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor.
@en
The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor.
@nl
prefLabel
The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor.
@en
The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor.
@nl
P2093
P50
P1476
The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor
@en
P2093
Gualtieri Mariani
Manuela Bernabei
Maria Luisa Dupuis
Maurizio Cianfriglia
P356
10.1016/J.BCMD.2010.03.008
P577
2010-05-04T00:00:00Z